Venture capital operator specialized in early stage investments in biotech startups close to clinical testing and development and companies active in the development of new high potential drugs, born from the Italian research network, both local and international. The goal is to identify and support new companies that develop potential drugs capable of revolutionizing the current therapeutic scenario in pathologies with limited therapeutic alternatives.

Last update: 21/09/2020